CORE C. IMMUNE ASSAY, FLOW CYTOMETRY AND GENE PROFILING This Core will support the Projects of this program project by providing flow cytometry and gene expression profiling services and by performing in vitro functional assays to monitor the immune status of subjects participating in clinical trials. For the clinical trial described in Project 1, the Core will be used to document the development of T cell tolerance to donor or host alloantigens, and assess the ability of the reconstituted patients to mount an immune response to newly introduced as well as recall antigens. For all four Projects the Core will provide flow cytometry based cellular phenotype analysis including the determination of adequate host T cell depletion and the monitoring of T cell recovery following hematopoiefic progenitor cell transplantation for the patients in the clinical trials (Project 1) and for cell phenotype analysis and purification (Projects 2-4). The Core will also provide gene expression profiling to idenfify genes associated with clinical immune tolerance in transplant recipients (Project 1), identify specific cell types expressing these genes (Projects 1 and 4) or identify genes that are differentially expressed in functional subsets of dendritic cells (Project 4).
Some patients tolerate transplanted organs without the need for dangerous immunosuppressive drugs. The goal of this Core is to support the effort in all of the Projects to identify the cells, genes and substances required for this tolerant state. If we are successful, future organ transplant recipients may no longer need to be treated with such toxic drugs.
|Pierini, Antonio; Strober, William; Moffett, Caitlin et al. (2016) TNF-Î± priming enhances CD4+FoxP3+ regulatory T-cell suppressive function in murine GVHD prevention and treatment. Blood 128:866-71|
|Strober, Samuel (2016) Use of hematopoietic cell transplants to achieve tolerance in patients with solid organ transplants. Blood 127:1539-43|
|Pierini, Antonio; Alvarez, Maite; Negrin, Robert S (2016) NK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell Engraftment. Stem Cells Int 2016:9025835|
|MÃ¼ller, Antonia M S; Florek, Mareike; Kohrt, Holbrook E K et al. (2016) Blood Stem Cell Activity Is Arrested by Th1-Mediated Injury Preventing Engraftment following Nonmyeloablative Conditioning. J Immunol 197:4151-4162|
|Spitzer, Matthew H; Gherardini, Pier Federico; Fragiadakis, Gabriela K et al. (2015) IMMUNOLOGY. An interactive reference framework for modeling a dynamic immune system. Science 349:1259425|
|Pierini, Antonio; Colonna, Lucrezia; Alvarez, Maite et al. (2015) Donor Requirements for Regulatory T Cell Suppression of Murine Graft-versus-Host Disease. J Immunol 195:347-55|
|Pan, Yuqiong; Leveson-Gower, Dennis B; de Almeida, Patricia E et al. (2015) Engraftment of embryonic stem cells and differentiated progeny by host conditioning with total lymphoid irradiation and regulatory T cells. Cell Rep 10:1793-802|
|Kim, Byung-Su; Nishikii, Hidekazu; Baker, Jeanette et al. (2015) Treatment with agonistic DR3 antibody results in expansion of donor Tregs and reduced graft-versus-host disease. Blood 126:546-57|
|Pierini, Antonio; Schneidawind, Dominik; Nishikii, Hidekazu et al. (2015) Regulatory T Cell Immunotherapy in Immune-Mediated Diseases. Curr Stem Cell Rep 1:177-186|
|Schneidawind, Dominik; Baker, Jeanette; Pierini, Antonio et al. (2015) Third-party CD4+ invariant natural killer T cells protect from murine GVHD lethality. Blood 125:3491-500|
Showing the most recent 10 out of 55 publications